Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 6Breast Neoplasms 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Endometrial Neoplasms 2Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × copanlisib × Clear all
NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 1/2 Terminated
17 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡